UNSPSC 51361805: Metomidate

This classification denotes a sedative and hypnotic with the molecular formula C13H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z18ZYL8Y51, chemically known as 1h-imidazole-5-carboxylic acid, 1- (1-phenylethyl)-, methyl ester, monohydrochloride but generally known as metomidate, which bears US NIH Compound Identifier 21474. European Medicines Agency schedules Metomidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08907MIG.

UNSPSC 51361805 Metomidate is a Commodity code that represents a specific pharmaceutical agent, yet recent state and local procurement activity under this code does not reflect direct metomidate purchases. Instead, issuing bodies are soliciting broader pharmaceutical and drug-management products and services that encompass naloxone, generic pharmaceuticals, over-the-counter medications, and direct-to-manufacturer prescription programs. State and local governments buying under this code's family are seeking to expand access to emergency medications, manage pharmaceutical supply chains through cooperative purchasing arrangements, and evaluate new pharmacy benefit delivery models. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that pool demand across participating state and local government facilities.

Recent activity spans Florida, Minnesota, Oregon, and Texas. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the procurement included FEMA funding and required E-Verify compliance and workers' compensation insurance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP posted January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission posted a Request for Information (RFI) on April 3, 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling potential future formal solicitation for direct contracting models between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager channels.